Specifically, mechanisms should not be required to accept biological observations or phenomena in the risk assessment process, and non-monotonic and monotonic dose responses should be treated equally in these assessments.
RRT may further modify the pharmacokinetic and dynamic changes of parent compounds/metabolites; drug dose and response should be evaluated when RRT is started and stopped.
Therefore, the plausibility of the observed biological response should be considered in evaluating the dose response relationship.
(Every response should be recorded).
Dose response should also be established to achieve the lowest effective dose.
Dose response functions should be constructed for each treatment that are sensitive to these four factors.
In addition, when considering the differences in strain susceptibility to chemical carcinogens, a new dose response curve should be run in the strain of interest.
Absent such information, the mixture dose-response assessment should be based on the dose-response assessments of individual chemicals, and these assessments on individual chemicals cannot in themselves incorporate background exposures to other chemicals.
